The Benavente Lab research interests focus on understanding childhood cancers and contributing to their targeted therapeutics. Our research particularly aims to study the chromatin remodeling processes that establish the normal epigenetic landscape in developing tissues, how it can be perturbed to promote cancer, and provide insight for the development of new therapies for pediatric solid tumors.
Retinoblastoma and osteosarcoma are two of the most common forms of childhood solid tumors. Children with hereditary retinoblastoma -who have a germline mutation in the RB1 gene- are predisposed to osteosarcoma later in their life. Despite recent progress in clinical outcomes in retinoblastoma, survivorship is often accompanied by total or partial blindness. On the other hand, the survival rate for osteosarcoma is just over 50%. This underscores the need to identify the molecular mechanisms responsible for disease progression and to develop more effective drugs.
- Retinoblastoma and targeted therapeutics
- Osteosarcoma and targeted therapeutics
- Epigenomics of pediatric solid tumors
- Human in vitro model of retinoblastoma
Given that the RB/E2F pathway is virtually inactivated in every cancer, through our studies of role of the RB/E2F pathway in regulation of the epigenetic machinery in retinoblastoma and osteosarcoma we aim to help improve the therapeutic options for other cancers.